ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

SHAREHOLDER ALERT: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against CorMedix Inc. (CRMD)

Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of CorMedix Inc. (NASDAQ: CRMD) between July 8, 2020 and May 13, 2021, for violations of the Securities Exchange Act of 1934. CorMedix is a biopharmaceutical company that develops and commercializes therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the U.S. and internationally. CorMedix's lead product candidate is DefenCath, a novel antibacterial and antifungal solution designed to prevent costly and dangerous catheter-related bloodstream infections ("CRBSIs").

If you purchased shares of CorMedix Inc. (CRMD) between July 8, 2020 and May 13, 2021, you have until September 20, 2021, to ask the court to appoint you lead plaintiff for the class. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

If you suffered a loss due to CorMedix Inc.'s misconduct, click here.

CorMedix Inc. (CRMD) Failed to Disclose Deficiencies in the Manufacturing Process of its Lead Product Candidate

According to the complaint, CorMedix completed submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for DefenCath. On March 1, 2021, CorMedix announced "that the [FDA] cannot approve the [NDA] for DefenCath … in its present form due to "concerns at the third-party manufacturing facility" that were currently unknown to CorMedix. The announcement also revealed that the "FDA is requiring a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vials despite an existing in-process control to demonstrate fill volume within specifications." On this news, CorMedix's stock price fell $5.98, or almost 40%, to close at $9.02 per share on March 1, 2021. Over the next several months, the Company revealed additional set-backs, including the need to make "adjustments in the process" and finally, the need to generate additional data "to address the deficiencies identified by the FDA." These disclosures have led to a further decline in the stock price, which trades at around $6.23 per share.

Contact us to learn more:

Aaron Dumas

(800) 350-6003

adumas@robbinsllp.com

Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. Founded in 2002, Robbins LLP has years' of experience successfully championing the rights of shareholders and holding companies and their corporate executives accountable for their wrongful misconduct. To be notified if a class action against CorMedix Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.